Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Inventory (2018 - 2025)

Dna X filings provide 8 years of Inventory readings, the most recent being $11.0 million for Q3 2025.

  • On a quarterly basis, Inventory fell 11.22% to $11.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $11.0 million, a 11.22% decrease, with the full-year FY2024 number at $10.6 million, up 62.97% from a year prior.
  • Inventory hit $11.0 million in Q3 2025 for Dna X, up from $9.9 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $12.4 million in Q3 2024 to a low of $185000.0 in Q4 2021.
  • Median Inventory over the past 5 years was $6.5 million (2023), compared with a mean of $7.0 million.
  • Biggest five-year swings in Inventory: tumbled 98.37% in 2021 and later surged 2013.51% in 2022.
  • Dna X's Inventory stood at $185000.0 in 2021, then surged by 2013.51% to $3.9 million in 2022, then surged by 66.68% to $6.5 million in 2023, then skyrocketed by 62.97% to $10.6 million in 2024, then increased by 3.44% to $11.0 million in 2025.
  • The last three reported values for Inventory were $11.0 million (Q3 2025), $9.9 million (Q2 2025), and $8.6 million (Q1 2025) per Business Quant data.